Literature DB >> 6315426

Pharmacokinetic and microbial susceptibility studies of ceftriaxone.

J D Baumgartner, M P Glauser.   

Abstract

The in vitro activity of ceftriaxone, a new parenteral cephalosporin, was tested against 450 strains isolated from blood cultures and compared with that of various other antibiotics. The compound was comparable to cefotaxime for all species tested. It was more potent than cefoperazone, cefamandole and ticarcillin in inhibiting Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, indole-positive Proteus spp. and Serratia marcescens). The MIC95 of ceftriaxone for these strains was 0.5 microgram/ml. The drug was less active against Staphylococcus aureus than cefamandole, cloxacillin and vancomycin, but most isolates were inhibited by 4 micrograms/ml. Against Pseudomonas aeruginosa, ceftriaxone was comparable in activity to ticarcillin (MIC95 = 64 micrograms/ml), and inferior to cefoperazone, ceftazidime and cefsulodine. Levels of ceftriaxone in serum and various body fluids were determined by bio-assays. Due to its very long half-life (8 h), ceftriaxone serum levels 24 h after i.v. or i.m. injection of 1 and 2 g were still above the MIC95 of all strains tested except Pseudomonas aeruginosa. Levels in bile, synovial and cerebro-spinal fluids were high.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315426     DOI: 10.1007/bf02013916

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  6 in total

1.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

2.  In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.

Authors:  K Shannon; A King; C Warren; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

3.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.

Authors:  J D Baumgartner; M P Glauser
Journal:  Arch Intern Med       Date:  1983-10

5.  Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.

Authors:  T C Eickhoff; J Ehret
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

6.  In vitro evaluation of Ro 13-9904.

Authors:  A M Hinkle; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

  6 in total
  2 in total

1.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

2.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.